The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)

The purpose of this research is to see the effect of triplet therapy with atezolizumab, bevacizumab, and memantine in treatment of your hepatocellular carcinoma.

Trial Details

NCT ID
NCT06789757
Phase
PHASE2
Sponsor
Inova Health Care Services
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Memantine Hydrochloride
  • Bevacizumab
  • Atezolizumab
Locations (sample)
  • Fairfax, Virginia, United States|38.84622,-77.30637
  • Falls Church, Virginia, United States|38.88233,-77.17109

Key Eligibility Criteria

  • Age 18 or older.
  • Patients have newly diagnosed and previously untreated, histologically or radiologically confirmed hepatocellular carcinoma with at least one lesio…
  • Patient's cancer must be deemed locally advanced and unresectable
  • Patients must have a Childs-Pugh cirrhosis score of A5 or A6.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →